Spyre Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYRE research report →
Range $115 – $130
Price Chart
About the company
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin.
- CEO
- Cameron Turtle
- IPO
- 2016
- Employees
- 125
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on SYRE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.88B
- P/E
- -34.24
- PEG
- 0.42
- P/S
- 98.45
- P/B
- 7.89
- EV/EBITDA
- -32.63
- Div Yield
- 0.00%
- Gross Margin
- 50.00%
- Op Margin
- -276.45%
- Net Margin
- -291.57%
- ROE
- -29.82%
- ROIC
- -23.61%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-171,653,000+0.0%
- Op Income
- $-209,562,000
- Net Income
- $-155,203,000+25.4%
- EPS
- $-1.98+37.7%
- OCF Growth
- -7.5%
- FCF Growth
- -7.5%
- 52W High
- $110.64
- 52W Low
- $23.01
- 50D MA
- $92.22
- 200D MA
- $77.98
- Beta
- 3.23
- RSI (14)
- 46
- Avg Volume
- 1.27M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aeglea said 2018 was a productive year, highlighted by progress in pegzilarginase, new pipeline programs, and a $69 million financing that extends cash runway into the PEACE readout.· March 7, 2019
- Pegzilarginase advanced in both rare disease and oncology, with Phase 3 PEACE design aligned with FDA and EMA and first patient dosing expected in Q2 2019.
- The company reported no objective responses in the SCLC cohort, but management said safety was confirmed and Phase 2 combo enrollment is underway.
- New pipeline programs for homocystinuria and cystinuria moved into IND-enabling work, with IND filings targeted for 1Q20 and 2H20, respectively.
- A February financing raised $69 million gross and lifted pro forma cash to about $139 million at Dec. 31, 2018.
- Management said the cash runway should extend through the PEACE pivotal trial readout in 1Q21.
Aeglea reported a fourth-quarter 2018 net loss of $14.9 million, or $0.62 per share, versus a net loss of $6.5 million, or $0.39 per share, in Q4 2017. Fourth-quarter 2018 R&D expense was $11.8 million versus $5.8 million a year earlier, and G&A expense was $3.5 million versus $2.3 million. All 2018 and 2017 revenue came from a $19.8 million cancer research grant, with the full grant revenue recognized over the life of the award. The company said it completed a February financing for $69 million gross proceeds, resulting in pro forma cash of approximately $139 million at Dec. 31, 2018 and expected cash runway through the PEACE pivotal trial readout in 1Q21. Forward-looking guidance included first patient dosing in PEACE in Q2 2019, top-line SCLC combination data in 1H20, homocystinuria IND filing in 1Q20, and cystinuria IND filing in 2H20.
Anthony Quinn struck an upbeat tone, framing 2018 as a year of substantial progress and saying the company is well positioned for 2019. He emphasized three priorities: advancing pegzilarginase in arginase 1 deficiency, continuing oncology development, and pushing new pipeline assets toward the clinic. He also highlighted the February financing as a key balance-sheet step that supports execution into 2021.
Charles York focused on financing strength, liquidity, and spending plans. He said the February financing added $69 million gross proceeds and lifted pro forma cash to about $139 million at Dec. 31, 2018, with runway expected through the PEACE readout in 1Q21. He also quantified Q4 losses and expenses, with net loss of $14.9 million, R&D of $11.8 million, and G&A of $3.5 million, and guided to quarterly burn of $12 million to $15 million in 2019, except for Q1 at $15 million to $17 million due to pipeline and manufacturing ramp.
Analysts pressed on how the new cystinuria and homocystinuria programs will produce clinical proof of concept, and management said homocystinuria will likely show early readouts from homocystine lowering in patients, while cystinuria has the advantage of an FDA-listed surrogate endpoint. Questions also focused on the SCLC program and the rationale for moving to Phase 2 despite no objective responses; management said safety was consistent with prior experience, no dose-limiting toxicities were seen, and the selected 0.27 mg/kg dose was supported by the Phase 1 data. Another question addressed ARG1-D prevalence, where management said their estimate of at least 600 patients in major markets may be conservative because they have already identified more than 170 patients. The company also confirmed it has Rare Pediatric Disease designation, but said any pediatric voucher would only be available after approval.
The call showed multiple shots on goal: a pivotal Phase 3 in arginase 1 deficiency, an ongoing oncology combination program, and two new rare-disease pipeline assets. Management said the PEACE design is aligned with regulators and that early clinical improvements in mobility and adaptive behavior reinforce confidence in the program.
The oncology program still lacks objective responses in the SCLC cohort, so the clinical signal remains limited even as Phase 2 moves ahead. R&D spending and cash burn are rising, and the company is still years away from key readouts and potential filings for the new pipeline programs.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.8%
- Shares Outstanding
- 94.97M
- Float Shares
- 85.27M
of shares held by institutions
276 13F filers
Buy/sell ratio 0.11. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 13.50M | ▲ 470.41K |
| Blackrock, Inc. | 6.78M | ▲ 272.88K |
| Perceptive Advisors LLC | 4.32M | ▲ 536.27K |
| Rtw Investments, LP | 4.25M | ▲ 80.00K |
| Vanguard Portfolio Management LLC | 4.06M | ▲ 1.73M |
| Vanguard Group Inc | 4.04M | ▲ 984.34K |
| Paradigm Biocapital Advisors LP | 3.84M | ▲ 1.88M |
| Vanguard Capital Management LLC | 3.75M | ▲ 302.11K |
| State Street Corp | 3.53M | ▲ 476.45K |
| Venrock Adviser, LLC | 2.99M | ▼ 700.00K |
| Price T Rowe Associates Inc | 2.96M | ▲ 1.36M |
| Driehaus Capital Management LLC | 2.80M | ▲ 8.38K |
Held by 407 ETFs
Biggest fund positions in SYRE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | King-Jones Heidy | other | 28,933 |
| Oct 1, 26 | King-Jones Heidy | other | 28,933 |
| Oct 1, 26 | King-Jones Heidy | sell | 400 |
| Oct 1, 26 | King-Jones Heidy | sell | 16,605 |
| Oct 1, 26 | King-Jones Heidy | sell | 7,228 |
| Oct 1, 26 | King-Jones Heidy | sell | 2,100 |
| Oct 1, 26 | King-Jones Heidy | sell | 2,600 |
| Oct 1, 26 | Turtle Cameron | sell | 600 |
| Oct 1, 26 | Turtle Cameron | sell | 2,683 |
| Oct 1, 26 | Turtle Cameron | sell | 2,638 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SYRE coverage
Recent articles, reports, and earnings notes.
No research on SYRE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SYRE report →Spyre Therapeutics, Inc. (SYRE) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com · Nov 6
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 3
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
globenewswire.com · Oct 18
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
seekingalpha.com · Oct 7
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
globenewswire.com · Oct 5
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
globenewswire.com · Oct 5
Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale
defenseworld.net · Oct 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.